- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Endometrial cancer
- Meeting Date: July 2025
- Public Summary Document (PSD) July 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) July 2025 PBAC Meeting - (Word)
Pembrolizumab – July 2025
Pembrolizumab (endometrial cancer); Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
Last updated
9 July 2025